(19)
(11) EP 1 340 750 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
19.10.2005 Bulletin 2005/42

(45) Mention of the grant of the patent:
17.08.2005 Bulletin 2005/33

(21) Application number: 01981033.2

(22) Date of filing: 08.11.2001
(51) International Patent Classification (IPC)7: C07D 277/40, C07D 277/62, C07D 277/64, C07D 277/74, C07D 417/12, C07D 417/14, A61K 31/426, A61K 31/427, A61K 31/496, A61K 31/4709, A61K 31/4725, A61K 31/428, A61K 31/536, A61K 31/454, A61K 31/433, A61K 31/5415, A61K 31/439, A61P 31/22
(86) International application number:
PCT/JP2001/009790
(87) International publication number:
WO 2002/038554 (16.05.2002 Gazette 2002/20)

(54)

AMIDE DERIVATIVES

AMIDDERIVATE

DERIVES AMIDES

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

(30) Priority: 10.11.2000 JP 2000344354

(43) Date of publication of application:
03.09.2003 Bulletin 2003/36

(73) Proprietors:
  • Astellas Pharma Inc.
    Chuo-ku, Tokyo (JP)
  • Rational Drug Design Laboratories
    Tokyo 174-8612 (JP)

(72) Inventors:
  • KONTANI, Toru, c/o Yamanouchi Pharma. Co., Ltd.
    Tsukuba-shi, Ibaraki 305-8585 (JP)
  • MIYATA, Junji, c/o Yamanouchi Pharma. Co., Ltd.
    Tsukuba-shi, Ibaraki 305-8585 (JP)
  • HAMAGUCHI, Wataru, c/o Yamanouchi Pharma. Co. Ltd.
    Tsukuba-shi, Ibaraki 305-8585 (JP)
  • MIYAZAKI, Yoji, c/o Yamanouchi Pharma. Co., Ltd.
    Tsukuba-shi, Ibaraki 305-8585 (JP)
  • SUZUKI, Hiroshi, c/o Yamanouchi Pharma. Co., Ltd.
    Tsukuba-shi, Ibaraki 305-8585 (JP)
  • NAKAI, Eiichi, c/o Yamanouchi Pharma. Co., Ltd.
    Tsukuba-shi, Ibaraki 305-8585 (JP)
  • KAGEYAMA, Shunji, c/o Yamanouchi Pharma. Co., Ltd.
    Tokyo 174-8612 (JP)

(74) Representative: Bates, Philip Ian 
Reddie & Grose 16 Theobalds Road
London WC1X 8PL
London WC1X 8PL (GB)


(56) References cited: : 
WO-A1-00/29399
WO-A1-99/42455
 WO-A1-97/24343
US-A- 6 057 451
   
  • SIMONEAU BRUNO: 'Helicase-primase inhibitors as novel anti-HSV agents' CHIMIA vol. 53, no. 6, 1999, pages 297 - 298, XP002908530
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).